ArticleCureus2026
Evaluation of Serum Vascular Endothelial Growth Factor (VEGF) and Placental Growth Factor (PlGF) Levels in Unexplained Early Pregnancy Loss: A Case-Control Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly pregnancy loss, defined as spontaneous termination of pregnancy before 20 weeks of gestation or fetal weight below 500 g, remains a common obstetric complication. While several etiological factors, such as genetic abnormalities and uterine defects, are established, nearly half of the cases remain unexplained, necessitating exploration of underlying biochemical mechanisms.
objectiveTo evaluate and compare serum levels of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in women with early pregnancy loss and healthy pregnant controls of similar gestational age and to assess the association and diagnostic performance of these angiogenic markers.
methodsA hospital-based case-control study was conducted involving 60 pregnant women aged 19-45 years with pregnancies of less than 20 weeks' gestation, including 30 cases of early pregnancy loss and 30 healthy pregnant controls with viable intrauterine pregnancies of comparable gestational age. Participants were recruited from the Department of Obstetrics and Gynecology of HSK Hospital, Bagalkot, and biochemical analysis was performed at Bharatiya Lingayat Development Educational Association (Deemed to be University) (BLDE [DU]), Vijayapura. Serum VEGF and PlGF levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using IBM Corp. Released 2014. IBM SPSS Statistics for Windows, Version 20. Armonk, NY: IBM Corp., applying chi-square and independent t-tests, with results expressed as mean ± standard deviation (SD). Receiver operating characteristic (ROC) curve analysis was performed to assess diagnostic performance and derive optimal cut-off values.
resultsSerum VEGF and PlGF levels were significantly reduced in cases compared to controls (p < 0.05), indicating impaired angiogenesis in early pregnancy loss. ROC analysis showed adequate diagnostic performance for VEGF and excellent diagnostic performance for PlGF in differentiating cases from controls within this case-control sample.
conclusionReduced serum VEGF and PlGF levels are associated with early pregnancy loss and may serve as adjunctive diagnostic biomarkers for identifying altered angiogenic profiles in affected women after validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.